Population pharmacokinetic study of benznidazole in pediatric chagas disease suggests efficacy despite lower plasma concentrations than in adults
<b>Introduction:</b> Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology information on the drug is scarce....
Guardado en:
| Autores principales: | Altcheh, J., Moscatelli, G., Mastrantonio Garrido, Guido Enrique, Moroni, S., Giglio, N., Marson, María Elena, Ballering, G., Bisio, M., Koren, G., García Bournissen, F. |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/85409 |
| Aporte de: |
Ejemplares similares
-
Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016) -
Development of UV/HPLC methods for quantitative analysis of benznidazole in human plasma and urine for application in pediatric clinical studies
por: Marson, María Elena, et al.
Publicado: (2013) -
Pediatric Clinical Pharmacology Studies in Chagas Disease
por: Garcia Bournissen, Facundo, et al.
Publicado: (2009) -
A Simple and Efficient HPLC Method for Benznidazole Dosage in Human Breast Milk
por: Marson, María Elena, et al.
Publicado: (2013) -
Identification of N-benzylacetamide as a major component of human plasmatic metabolic profiling of benznidazole
por: Marson, María Elena, et al.
Publicado: (2015)